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Abstract
We identified the molecular target by histone deacetylase (HDAC) inhibitors for exploring their
potential prostate cancer (PCa) therapy. Upon HDAC inhibitors-treatment, LNCaP cell growth
was suppressed, correlating with increased cellular prostatic acid phosphatase (cPAcP) expression,
an authentic protein tyrosine phosphatase. In those cells, ErbB-2 was dephosphorylated, histone
H3/H4 acetylation and methylation increased and cyclin proteins decreased. In PAcP shRNA-
transfected C-81 cells, valproic acid (VPA) efficacy of growth suppression was diminished.
Further, VPA pre-treatment enhanced androgen sensitivity of C-81, C4-2 and MDA PCa2b-AI
cells. Thus, cPAcP expression is involved in growth suppression by HDAC inhibitors in PCa cells,
and VPA pre-treatments increase androgen sensitivity.
Keywords
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1. Introduction
Prostate cancer (PCa) is the most commonly diagnosed solid tumor and the second leading
cause of cancer death in men in United States [1]. Despite the fact that androgen ablation
therapy provides the first line of treatment for metastatic PCa, effective therapy for relapsed
HR or CR PCa is limited. Further modalities are required for treating this patient population.
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The epigenetic modifications including DNA methylation and histone modifications play an
important role in the patho-physiology of cancer [2,3]. Methylation of cytosine in CpG
islands leads to gene silencing and is closely associated with cancer development. However,
about 40% of human gene promoters do not contain the CpG island; other epigenetic factors
such as chromatin modification and nucleosome remodeling are involved in establishing this
mode of regulation [3,4]. Histone modifications predominantly acetylation and deacetylation
by histone acetyl transferases and HDACs are the major events for epigenetic regulation [4].
HDAC activity is enhanced in various cancers and histone deacetylation is one of common
mechanisms used by cancer cells to down-regulate tumor suppressor genes and/or to up-
regulate tumor promoting genes [3,4]. Several lines of evidence show that HDACs are
abundantly expressed and up-regulated in PCa cells and cancerous tissues [2,5,6]. Therefore
HDAC inhibitors, for example, VPA, are in clinical trials for PCa therapy [7]. However, the
functional targets regulated by HDAC inhibitors remain further identification.
Human PAcP is the major phosphatase in normal well-differentiated prostate epithelial cells.
In those cells, there are two forms of PAcP: the cellular form (cPAcP) and the secretory
form (sPAcP), differing in several biochemical properties [8-10]. The serum activity of
sPAcP is frequently elevated in PCa patients and correlated with tumor progression [11,12].
As a consequence, serum sPAcP was used as a surrogate marker for monitoring PCa until
the availability of PSA [12]. Several lines of evidence show that cPAcP level negatively
correlates with prostate carcinogenesis, i.e. its cellular level decreases in PCa cells, lower
than in adjacent non-cancerous cells, despite the fact that sPAcP is elevated in the
circulation [13-17]. Further, cPAcP activity inversely correlates with the growth rate of
prostate epithelia and PCa cell lines [13-15,18-20]. It is thus proposed that cPAcP functions
as a negative growth regulator of prostate epithelia [10,18,19,21]. This cPAcP function is at
least in part due to the fact that this enzyme possesses the intrinsic protein tyrosine
phosphatase activity [10,15,22,23]. In prostate epithelia, cPAcP dephosphorylates HER-2/
ErbB-2/Neu at its phosphotyrosine residues and down-regulates its kinase specific activity,
which is associated with diminished growth rates and reduced tumorigenicity of xenograft
tumors [15,18,24-26]. Conversely, knockdown cPAcP expression by shRNA associates with
hyper-tyrosyl phosphorylation of HER-2 and activation of its downstream signaling, which
results in CR growth in culture and tumor development in female xenograft animals
[10,27,28]. Further, in PAcP-knockout mice, prostates develop adenocarcinomas
spontaneously [29]. These observations provide insights into one of the molecular
mechanisms involved in CR PCa progression. Despite the importance of cPAcP in prostate
carcinogensis, the molecular mechanism by which the expression of cPAcP is decreased or
silenced in PCa cells remains an enigma.
In this communication, we explored the functional molecules targeted by HDAC inhibitors
and concurrently, investigated the regulation of cPAcP expression by epigenetic events
including histone acetylation and methylation in AR-positive, androgen-independent PCa
cells, representing the majority of advanced PCa population in clinic [20,30]. We used
LNCaP C-81 cells as the model system because these cells express functional AR, secrete
PSA under androgen-deprived conditions and exhibit intracrine ability as CR PCa in clinic
[20,30,31]. Our data provide strong evidence for the role of cPAcP in growth suppression by
HDAC inhibitors and the regulation of cPAcP expression by epigenetic control in PCa.
Importantly, VPA-treated C-81 cells obtained the enhanced androgen sensitivity of cell
growth and PSA expression. Similar effects by VPA-pretreatment on androgen sensitivity
were also observed in androgen-independent LNCaP C4-2 and MDA PCa2b-AI cells. The
results thus have important clinical impacts on developing novel therapy toward advanced
CR PCa.
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2. Materials and methods
2.1. Materials
RPMI 1640 medium, gentamicin, FBS and trypsin/EDTA reagents were purchased from
Invitrogen Corporation (Carlsbad, CA). Charcoal/dextran-treated, certified FBS was from
Atlanta Biologicals (Lawrenceville, GA, USA). Acrylamide, protein molecular weight
standard markers and Protein Estimation Kit were obtained from Bio-Rad (Hercules, CA).
The ECL reagent kit was purchased from Pierce Biotechnology Inc. (Rockford, IL). FBS,
histone deacetylase inhibitors including NaB, VPA, Trichostatin A and anti-?-Actin Ab
(AC-15) were from Sigma (St Louis, MO, USA). Anti-phospho-HER-2/ErbB-2
(Tyr1221/1222) Ab was from Cell Signaling Technology (Beverly, MA). The Ab against
histone H3-acetylation (Lys-9/14) and histone H4-acetylation (Lys-16) were from Santa
Cruz Biotechnology (Santa Cruz, CA). The Ab against pY1248-ErbB-2, H3-methylation
(trimethyl-Lys27) and H4-methylation (trimethyl-Lys20) were from Upstate Biotechnology
(Lake Placid, NY, USA). Other Abs were procured from Santa Cruz Biotechnology (Santa
Cruz, CA). Anti-PAcP antiserum (ATM-3) was described previously [24].
2.2. Cell Culture
Human prostate carcinoma cell line LNCaP and MDA PCa2b was originally purchased from
the American Type Culture Collection (Rockville, MD). LNCaP C4-2 cells were purchased
from DIANON Company (Oklahoma City, OK). LNCaP cells were routinely maintained in
the regular medium, i.e., phenol red-positive RPMI 1640 medium supplemented with 5%
FBS, 2 mM glutamine and 50 ?g/ml gentamicin. MDA PCa2b cells were cultured in BRFF-
HPC1 medium containing 20 % FBS, 2 mM glutamine and 50 ?g/ml gentamicin [27,32].
LNCaP C4-2 cells were grown in DMEM/F12 medium containing 10 % FBS, 2mM
glutamine, 50 ?g/ml gentamicin, 1 mM sodium pyruvate, 2× vitamin C and 1× MEM non-
essential amino acid [33]. Cells were split once a week by trypsinization, which was defined
as one passage. The LNCaP PCa cell progression model was described originally by Lin et
al. [20] and further characterized by Igawa et al. [30] with passage number less than 33
defined as C-33, passage numbers between 80 and 120 as C-81. In these experiments, cells
with passage numbers between 100 and 115 were used. LNCaP C-81 cells exhibit many
biochemical properties similar to advanced CR PCa, including AR expression and PSA
secretion with rapid growth in the steroid-deprived condition [20,30] and obtaining
intracrine regulation [31]. Similarly, LNCaP C4-2 cells and the high passage MDA PCa2b
cells exhibit androgen-independent proliferation [27,32,33]. Since these high passage MDA
PCa2b cells obtain the androgen-independent phenotype, we named these cells as MDA
PCa2b-AI cells. In this set of experiments, the passage numbers of MDA PCa2b-AI cells
were between about 110 and 125.
2.3. Northern blot hybridization
Total RNA was prepared from LNCaP cells by the guanidine isothiocynate method [18,20].
Ten ?g each of total RNA sample were electrophoresed on 1.2% agarose gels containing
formaldehyde as a denaturing agent. After electrophoresis, the gel was stained with ethidium
bromide (EtBr) and visualized to ensure approximately equal amounts of RNA per lane,
then blotted to nitrocellulose membranes by standard techniques [18]. Filters were
hybridized and washed under stringent conditions as described previously [18,20]. cDNA
probes for PAcP were labeled with (?-32P)-dCTP using random oligonucleotide-primed
synthesis with a commercial system. GAPDH cDNA probes were used to detect GAPDH
mRNA as an internal control.
Chou et al. Page 3
Cancer Lett. Author manuscript; available in PMC 2012 December 8.
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t
2.4. Cell growth analysis
LNCaP C-33 and C-81 cells were plated with 1×104 cells/well in 12-well plates in regular
medium and treated with different concentrations of reagents as specified in each
experiment for 3 days. Cells were counted using a Cellometer Auto T4 Image-based cell
counter (Nexcelom Bioscience) [27]. Results shown are an average of three sets of
independent experiments performed in triplicates.
2.5. CAT reporter gene assay and cPAcP shRNA plasmid transfection
For CAT reporter gene assay, LNCaP C-81 cells were plated at a density of 1×104 cells/well
in 12-well plates and transfected with 0.1 ?g of PAcP promoter-reporter gene including
p779 and p1258, using Lipofectamine and Plus reagents in serum-free medium [34]. Four
hours after transfection, cells were fed with RPMI media containing 5% FBS for 24 hr. The
cells were then treated with different concentrations of NaB for 48 hr. Cells were then
harvested, lysed and the CAT activity in cell lysates was determined. For shRNA plasmid
transfections, C-81 cells were plated at a density of 1×105 cells/well in 6-well plates for 72
hr and then transfected with PAcP shRNA-126 plasmids [27]. Control cells were transfected
with the vector containing the scramble DNA. Five hours after transfection, the cells were
fed with RPMI media containing 10% FBS for 24 hr. The cells were then treated with 1mM
VPA for 2 or 3 days. Total cell lysate proteins from 3 days treatment were analyzed for
cPAcP protein expression.
2.6. Effect of HDAC inhibitor on the androgen sensitivity of cell growth
For analyzing the androgen sensitivity of HDAC inhibitor-treated cells, LNCaP C-81, C4-2
and MDA PCa2b cells were plated at a density of 3×104, 3×104 and 1×105 cells/well,
respectively, in 6-well plates for 3 days and then treated with 1 mM VPA in regular medium
for 2 days. Subsequently, cells were maintained in a steroid-reduced medium plus or minus
10 nM 5?-dihydrotestosterone (DHT) for 2 or 3 days. Cells were then harvested, counted
and lysed for analyzing cPAcP, AR and PSA protein expression.
2.7. Immunoblotting
For detecting cellular proteins, subconfluent cells were harvested by scraping. The cell pellet
was rinsed with ice-cold 20 mM HEPES-buffered saline (pH 7.0) and then lysed in ice-cold
hypotonic cell lysis buffer containing protease and phosphatase inhibitors and the total
lysate protein was prepared accordingly [27]. An aliquot of total cellular lysate having
50-120 ?g protein was subjected to electrophoresis on SDS-polyacrylamide gels (7.5-12%
acrylamide) for western blot analyses [27]. The proteins of interest were visualized by an
ECL detection system. For rehybridization, the membranes were stripped with a stripping
buffer [27], blocked and re-probed with specific Abs.
2.8. Flow cytometry analysis
LNCaP C-81 cells were treated with 1 mM NaB, 1 mM VPA or 300 nM TSA for 48 hr. The
cells were then washed with ice-cold 20 mM HEPES-buffered saline (pH 7.0) and harvested
by trypsinization. A minimum of 1×106 cells was fixed with chilled 75% ethanol for at least
1 hr at 4°C. Cells were then incubated with ice cold Telford DNA staining reagent (50 ?g/ml
RNase A and 50 ?g/ml propidium iodide in HEPES) for overnight at 4°C. Data acquisition
and analyses were carried out using a flow cytometry system [35].
2.9. Statistical analysis
Each experiment was performed in triplicates, repeated 2-3 times and the mean and standard
error values were calculated. The significance of difference (p-value) was calculated using
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independent Student t-test and the p-value less than 0.05 was considered as significant
[20,35].
3. Results
3.1. Effect of NaB on cell growth and PAcP expression in AR-positive PCa cells
To explore the functional molecules targeted by HDAC inhibitors, we initially treated
LNCaP C-33 and C-81 cells with NaB, a classical HDAC inhibitor. Both cells express
functional AR; while C-33 cells are androgen-sensitive, C-81 cells obtain many biochemical
properties of advanced CR PCa, including rapid proliferation in a steroid-reduced condition
and intracrine regulation [15,20,30,31]. Cell growth analyses showed that NaB treatment is
associated with decreased cell proliferation, following a dose-dependent manner in both
C-33 and C-81 cells (Fig. 1A). Since cPAcP expression is associated with growth
suppression [26,27], we investigated NaB effect on cPAcP expression. Northern blot
analyses showed that in the absence of NaB, C-33 cells expressed a higher basal level of
PAcP mRNA than C-81 cells in which PAcP mRNA was only marginally detected (Fig.
1B). PAcP mRNA level was greatly elevated in both NaB-treated C-33 and C-81 cells,
following a bell-shape dose-responsive fashion. We further examined if NaB up-regulated
PAcP mRNA at the transcriptional level by analyzing its promoter (p779 and p1258) activity
utilizing the CAT reporter gene assay in C-81 cells because these cells express a very low
level of PAcP in control cells (Fig. 1B). The p779 promoter exhibited a low basal promoter
activity, as shown previously [34,36], and NaB had no effect on its reporter gene activity
(Fig. 1C). The p1258 promoter exhibited a high basal activity and was further activated by
NaB (Fig. 1C), in the face of growth suppression (Fig. 1A). Thus, NaB inhibits LNCaP cell
growth and concurrently induces the expression of PAcP, an authentic growth suppressor
[10,27], at the transcriptional level in these cells.
3.2. Effect of HDAC inhibitors on cPAcP protein levels in dosage and kinetic manner
We focused our efforts on examining NaB effect on PAcP expression at protein level, the
functional molecule, in C-81 cells since these cells exhibit the CR phenotype with a low
level of PAcP expression. In NaB-treated C-81 cells, cPAcP protein level elevated,
following a dose-dependent fashion (Fig. 2A). The 50 kDa protein is the mature
glycosylated form of PAcP protein, and the 42 kDa protein is its intermediate form protein
(Fig. 2A; [10,27]). Since NaB exhibits diverse activities other than HDAC inhibition, we
examined the effect of another HDAC inhibitor TSA on cPAcP protein expression in C-81
cells. Western blot analyses showed that cPAcP protein level is also elevated in TSA-treated
C-81 cells, following a dose-dependent manner (data not shown). We further examined VPA
effect on cPAcP protein expression since VPA exhibits an activity as a HDAC inhibitor and
is currently in clinical usages [4,7]. In VPA-treated C-81 cells, cPAcP protein level elevated
(Fig. 2B) and concurrently, cell growth decreased (data not shown), as seen by NaB (Fig.
1A). Therefore, HDAC inhibitors effectively suppress PCa cell growth and concurrently up-
regulate cPAcP expression in a dose-dependent fashion.
We investigated the kinetic effect of HDAC inhibitors on cPAcP protein expression in
LNCaP C-81 cells. As shown in Fig. 2C & 2D, NaB and VPA up-regulated the 50 kDa
mature form of cPAcP protein level in C-81 cells initially seen at 12 hr treatment, which was
greatly elevated at 24 hr and 48 hr time points (Fig. 2C & 2D). Thus, in HDAC inhibitor-
treated cells, increased cPAcP expression followed a time-dependent manner.
HDAC inhibitors have effects on histone acetylation and also methylation [37-39]. Due to
the clinical applicability of VPA, we focused on analyzing VPA effects on histone H3 and
H4 acetylation levels at the residue Lysine-9/14 and Lysine-16, respectively, for
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representation. In VPA-treated C-81 cells, histone H3/H4 acetylation levels were greatly up-
regulated in a time-dependent fashion between 0-12 hr and the up-regulated acetylation
levels were remained essentially the same from 12 hr to 48 hr. A low level of acetylation in
control cells was seen after a prolonged period of exposure (data not shown). The
methylation levels of histone H3 (Lys-27) and H4 (Lys-20) were only moderately up-
regulated seen at the 12 hr time point and through 48 hr (Fig. 2D). The data revealed that in
C-81 cells, the low level of PAcP gene expression is apparently in part down-regulated by
epigenetic mechanism including histone deacetylation and possibly demethylation.
3.3. Role of cPAcP expression in PCa cell growth suppression by HDAC inhibitors
To clarify the role of cPAcP expression in growth suppression by HDAC inhibitors, C-81
cells were transfected with shRNA plasmid to cPAcP and followed by VPA treatment.
Control cells were transfected with the vector containing scramble oligonucleotides. As
shown in Fig 3A, VPA suppressed the growth of vector alone transfected C-81 cells by
about 53% (column #1 vs. 2). Interestingly, the degree of VPA-growth suppression on
shPAcP-transfected C-81 cells was decreased by about 50%, i.e., from 53% growth
inhibition (Fig. 3A, column #2 vs. #1) reduced to 25% suppression (Fig. 3A, column #3 vs.
#1). Similar results were obtained from both 48 hr (Fig. 3A, left panel) and 72 hr (data not
shown) VPA treatments. Furthermore, western blot results validated that cPAcP protein
level was decreased by about 60% in shPAcP-transfected C-81 cells, lower than that in
control vector-transfected cells after 72 hr VPA-treatment (Fig. 3A, lane #3 vs. #2, right
panel). Thus, the data collectively support the notion that VPA efficacy on growth
suppression is in part through cPAcP expression.
3.4. Effect of HDAC inhibitor on the androgen sensitivity of PCa cells
cPAcP has been shown for its role in regulating androgen sensitivity of PCa cells which has
been reported in several publications [20,27,28]. We thus investigated the effect of HDAC
inhibitor on androgen sensitivity. Androgen-independent C-81 cells were treated with 1 mM
VPA for 48 hr followed by 10 nM DHT in a steroid-reduced condition. The usage of 10 nM
DHT is to determine if VPA pre-treatment has an effect on androgen sensitivity of these
cells. In the presence of DHT for 48 hr, the growth of VPA-pretreated C-81 cells increased
by about 70% (column #4 vs. #3, Fig. 3B, left panel, p<0.01), compared with only about
35% stimulation of control cells without VPA pre-treatment (column #2 vs. #1, Fig. 3B, left
panel). Western blot results validated that the cPAcP 50 kDa mature form protein was
elevated by VPA treatment (lane #3 vs. #1, Fig. 3B, right panel), which was decreased by
subsequent DHT-treatment (lane #4 vs. #3, Fig. 3B, right panel), inversely correlating with
cell growth stimulation [20,27,28]. In parallel, cellular PSA level was greatly elevated by
DHT in VPA-pretreated cells, about 1.5-fold of that in control cells without VPA-
pretreatment (lane #4 vs. #2, Fig. 3B, right panel). In those same cells, AR expression level
was not significantly changed after a total of 5 days treatments including 2-day by VPA and
3-day by DHT.
Due to the clinical importance of androgen sensitivity of PCa cells, we investigated whether
VPA treatment could similarly increase the degree of androgen stimulation in other
androgen-independent PCa cells, including LNCaP C4-2 and MDA PCa2b-AI cells. As
shown in Fig. 3C for LNCaP C4-2 cells and Fig. 3D for MDA PCa2b-AI cells, DHT alone
could increase the basal cell growth by approximately 10% (column #1 vs. #2).
Interestingly, DHT could greatly increase the growth of VPA-pretreated cells by about 70%
and 120%, respectively, (column #4 vs. #3, Fig. 3C & 3D, left panels). We subsequently
validated DHT effect by semi-quantifying PSA levels in those treated cells. Interestingly,
PSA basal level was elevated in VPA alone-treated MDA PCa2b-AI cells in the absence of
DHT (lane #3 vs. lane #1, Fig. 3D, right panel). Importantly, cellular PSA level was greatly
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elevated by DHT in VPA-pretreated cells, approximately 4- and 9-fold of that in control
cells without VPA-pretreatment, respectively (lane #4 vs. #2, Fig. 3C & 3D, right panels). It
should also be noted that due to the low expression level of AR protein in these two PCa cell
lines, prolonged hybridization with primary Ab to AR with longer exposure time periods
were required. In summary, VPA pre-treatment enhances DHT effect on the increments of
cell growth and PSA expression, which indicates that HDAC inhibitors can enhance
androgen sensitivity of PCa cells.
3.5. Effect of HDAC inhibitors on ErbB-2 tyrosyl phosphorylation level
We elucidated the molecular mechanism by which cPAcP contributes to HDAC inhibitor-
induced PCa cell growth suppression in C-81 cells as our model system. Cell density has a
significant effect on the expression of functional genes involving in growth regulation
[40-42]. In prostate epithelia, including LNCaP C-33 cells, cPAcP protein level elevates
when cell density increases in which cell growth is decreased [10,41]. Therefore, we
investigated the effect of 2-day VPA treatment on cPAcP protein expression in different cell
densities of C-81 cells. Western blot analyses showed that in the absence of VPA, the basal
level of cPAcP 50 kDa protein in higher density cells was slightly higher than that of lower
density cells (lane #3 & #5 vs #1, Fig. 4). In the presence of VPA, cPAcP protein level was
further elevated in the face of growth suppression by VPA. Nevertheless, neither the cell
density nor VPA had an effect on ?-actin protein level. Thus, VPA activates the silenced
cPAcP gene expression in C-81 cells under growth suppression, independent of the cell
density. Similar results were observed in NaB-treated cells (data not shown).
Since cPAcP can regulate ErbB-2 tyrosyl phosphorylation in PCa cells [15,24-27], we
analyzed ErbB-2 tyrosyl phosphorylation in 2-day VPA-treated cells. As shown in Fig. 4,
the basal phosphorylation level of Tyr1221/2 of ErbB-2 decreased in the high-density, slow-
growing cells in which cPAcP proteins level is elevated, concurring with the notion that
Tyr1221/2 are the primary sites of dephosphorylation by cPAcP [27]. Unexpectedly, the basal
phosphorylation level of Tyr1248 at ErbB-2 was increased in high-density cells (Fig. 4). In
VPA-treated cells, independent of cell density, cPAcP protein level elevated and ErbB-2
phosphorylation decreased at both Tyr1221/2 and Tyr1248 (Fig. 4), indicating cPAcP can
dephosphorylate both phosphorylation sites. Similar results of the inverse correlation
between cPAcP elevation and ErbB-2 dephosphorylation were observed in NaB-treated cells
(data not shown). ErbB-2 protein level was also diminished in HDAC inhibitors-treated cells
although to a lesser degree than that of phosphorylation level.
We analyzed acetylation and methylation levels of H3 and H4 in VPA-treated cells of
different densities. Western blot analyses showed that the acetylation levels of histone H3
and H4 were greatly up-regulated in 2-day VPA-treated LNCaP C-81 cells, following a cell
density-dependent fashion (Fig. 4); while there was a very low level of acetylation in the
absence of VPA which was seen after a long term exposure (data not shown). Interestingly,
in the absence of VPA, the basal levels of H3 Lys-27 and H4 Lys-20 methylation increased,
following the density of cells and correlating with basal cPAcP expression. VPA up-
regulated these methylation levels primarily in low density cells (Fig. 4). Nevertheless,
neither the cell density nor HDAC inhibitors had an effect on histone H3 and H4 protein
levels. Thus, in these HDAC inhibitors-treated cells, cPAcP protein increases and ErbB-2
Tyr1221/2 and Tyr1248 phosphorylation decreases, which apparently contribute to growth
suppression.
3.6. Effect of HDAC inhibitors on PCa cell proliferation and apoptotic proteins
We analyzed stress-induced signal pathway in 2-day VPA-treated C-81 cells. As shown in
Fig. 4, in the absence of VPA, increased phosphorylation levels of JNK/MAPK and p38/
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MAPK were following a cell density-dependent manner. In VPA-treated cells, the levels of
JNK and p38 MAPK phosphorylation and Bax pro-apoptotic protein were greatly elevated.
However, there was no significant change in bcl-2 anti-apoptotic protein level. Thus, HDAC
inhibitor-induced growth suppression is apparently in part via JNK and p38 MAPK
activation of Bax.
We examined cell cycle distribution and apoptosis in HDAC inhibitors-treated LNCaP C-81
cells. Flow cytometry analyses showed that approximately 60% and 20% control cells were
at the G1- and S-phase, respectively, of the cell cycle (Fig. 5A). HDAC inhibitors caused the
accumulation of cells (70-75%) in the G1-phase with only 3-6% cells at S-phase, indicating
diminished cell growth as observed in Fig. 1A. Further, HDAC inhibitors induced a
significant increase of apoptosis in C-81 cells, compared with control cells (Fig. 5A,
p<0.01). Interestingly, among HDAC inhibitors examined, TSA exhibited the least efficacy
on cell cycle arrest and apoptosis induction in C-81 cells.
We further investigated the effects of HDAC inhibitors on cell cycle proteins. Western blot
results (Fig. 5B) showed that the expression levels of cyclin B1 and D1 were greatly
abolished by VPA and to a lesser degree by NaB and TSA after 2-day treatment. On the
contrary, the expression level of p21, a cyclin-dependent kinase inhibitor protein, was
greatly increased by NaB and VPA, and to a much lesser degree by TSA (Fig. 5B).
Nevertheless, ?-actin was not changed in HDAC inhibitor-treated cells. Unexpectedly,
HDAC inhibitors did not have an effect on the expression level of PCNA, a cell proliferation
marker, despite the observed growth inhibition. Further analyses showed the down-
regulation of AR and intracellular PSA (cPSA) in VPA-treated C-81 cells and to a lesser
degree in NaB-treated cells; while there was no significant change in TSA-treated cells (Fig.
5B). In these HDAC inhibitors-treated cells (Fig. 5B), cPAcP protein level was inversely
correlated with ErbB-2 tyrosyl phosphorylation and was positively correlated with H3/H4
acetylation and methylation. The data collectively indicate that HDAC inhibitors suppress
androgen-independent, AR-positive PCa cells in part via cPAcP induction for ErbB-2
dephosphorylation, leading to cell cycle arrest and apoptosis.
4. Discussion
Epigenetic regulation including histone modifications plays critical roles in tumor initiation
and progression. In PCa, HDAC activity is increased in their pre-malignant and malignant
stages [2,38,43]. Therefore, HDAC inhibitors are emerging as an exciting class of potential
anticancer agents [5,6,38]. HDAC inhibitors including NaB and VPA have been examined
for antitumor activity in phase I and II clinical trials, respectively [2,7,44,45]. Among them,
VPA exhibits an efficacy on PCa cell growth [46,47] and xenograft tumor suppression [46].
However, the molecular mechanism and the functional targets of these HDAC inhibitors in
PCa remain further illustration for exploring their potential uses in PCa therapy.
The restoration of cPAcP expression in PCa cells may provide a new avenue for treating
advanced CR PCa in which the expression of PAcP is decreased or silenced. The notion is
supported by the observation that treatment of androgen-independent LNCaP C-81 cells
with HDAC inhibitors leads to their growth suppression, which correlates with elevated
cPAcP expression. Conversely, knockdown cPAcP expression by pre-transfecting with
shRNA reduces growth suppression by VPA (Fig. 3A, column #2 vs. #3). The data
collectively support the notion that cPAcP expression contributes to growth suppression
efficacy by VPA. Importantly, the pre-treatment of HDAC inhibitor enhances the androgen-
sensitivity of LNCaP C-81 and C4-2 and MDA PCa2b-AI cells (Fig. 3B, 3C & 3D). The
data imply that intermit treatments with HDAC inhibitors may prolong the efficacy of
androgen ablation therapy. Nevertheless, it should be pointed out that in VPA-treated C-81
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cells, different AR and PSA protein levels were observed in Fig. 3B vs. Fig. 5B; while the
PSA level correlates with AR level in respective experiments. Because AR level in PCa cells
is regulated by a dynamic process, and also because Fig. 3B was generated from cells with a
total of 5-day treatment including 2-day by VPA and 3-day by DHT while Fig. 5B was from
cells of 2-day VPA treatment, we thus proposed it is in part caused by different protocols
with different time periods of treatments. Further exploration of this avenue is apparently
timely important in developing novel strategies for treating CR PCa.
Another finding in this study is that HDAC inhibitors up-regulate the expression of PAcP
gene. Despite the fact that cPAcP can function as a tumor suppressor [26,27,29], and its
decreased expression correlates with the CR phenotype [27], the molecular mechanism of its
loss of expression in PCa cells remains an enigma. Southern blot analyses reveal that PAcP
gene is apparently retained intact in PAcP-null cells [48]. Interestingly, the promoter of
PAcP gene does not contain the classical CpG island (Klinkebiel D, Christman JK and Lin
MF; unpublished observations). The involvement of DNA methylation in silencing PAcP
gene requires further investigation. In this study, the expression of cPAcP is elevated in
HDAC inhibitors-treated AR-positive PCa cells and is associated with decreased cell
growth. In NaB-treated C-81 cells, the PAcP promoter activity increases as evidenced by the
reporter gene activity and the PAcP mRNA level is elevated (Fig. 1). Further, increased
expression of cPAcP is correlated with both increased acetylation and methylation of histone
H3/H4. Thus, the silencing of PAcP gene in LNCaP C-81 cells is at least in part down-
regulated by the epigenetic mechanism [48]. In those cells, histone deacetylation and/or
demethylation act cooperatively to silence the PAcP gene, leading to CR PCa progression.
Similarly effects by VPA on cPAcP expression are also observed in androgen-independent
C4-2 and MDA PCa2b-AI cells (Fig. 3C & 3D). Due to the potential importance of PAcP
expression in tumor suppression, the regulatory mechanism of PAcP expression requires
further exploration.
Our data also demonstrate that in the absence of VPA, the expression level of cPAcP protein
increased when the cell density increases and this increased expression of cPAcP correlates
with decreased ErbB-2 phosphorylation at Tyr1221/2 residues, but not Tyr1248 (Fig. 4). The
increased expression of cPAcP associates with slow growth of high density PCa cells may
imply that cPAcP is a functional molecule in down-regulating cell growth. The data also
indicate that Tyr1221/2 is the primary site of mediating cell proliferation signaling in these
PCa cells, concurring with biochemical observations [27]. Thus, inhibiting Tyr1221/2
phosphorylation at ErbB-2 may serve as a novel approach for CR PCa therapy.
Decreased EGFR and ErbB-2 proteins and their phosphorylation levels can be involved in
apoptosis via p38 MAPK-dependent activation of Bax in various cancer cells [49,50]. Our
results show that in HDAC inhibitors-treated PCa cells, increased cPAcP expression is
associated with decreased ErbB-2 protein and its tyrosyl phosphorylation; while stress signal
pathways JNK and p38/MAPK are activated and Bax is elevated in addition to the increased
apoptotic protein p21 in those cells. These data reveal that HDAC inhibitors-induced
suppression of HR PCa cells is in part via the inhibition of ErbB-2 downstream cell survival
signaling pathway where MAPK-dependent activation of Bax is involved. Additionally,
HDAC inhibitors can induce the expression of various tumor suppressor genes including
p21Waf/Cip1, p27Kip1 and p53, leading to cell cycle arrest at the G1- or G2/M phase [51,52].
In the present study, in HDAC inhibitors-treated androgen-independent, AR-positive PCa
cells, elevated cPAcP protein correlates with decreased cell-cycle up-regulating proteins
cyclin B1 and cyclin D1, and increased cyclin-dependent kinase inhibitor p21 protein.
Together, cell growth is arrested.
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5. Conclusion
Our study shows that in HDAC inhibitors-treated androgen-independent, AR-positive PCa
cells, growth suppression is associated with cPAcP induction, ErbB-2 dephosphorylation
and importantly, increased androgen sensitivity. The enhanced androgen sensitivity by
HDAC inhibitors pretreatment may indicate that intermit HDAC inhibitor treatments can
prolong the efficacy of androgen ablation therapy, therefore, further investigation is
necessary. Further, the effect of HDAC inhibitors on PCa cell growth suppression is at least
in part via up-regulating cPAcP expression. Therefore, the status of inactivation of PAcP
gene could potentially serve as a surrogate marker for identifying the lethal form of PCa.
Our results also reveal a novel mechanism of HDAC inhibitors on PCa growth suppression,
which can lead to the development of a new class of agents for treating CR PCa.
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Fig. 1.
Effect of NaB on cell growth and PAcP expression. LNCaP C-33 and C-81 cells were
treated with different concentrations of NaB for 3 days. Cells were harvested for (A) cell
growth analysis and (B) total RNA preparation. The expression of PAcP mRNA was
analyzed by northern blot analyses. The same membrane was hybridized with a GAPDH
probe as a loading control. (C) C-81 cells were transfected with the CAT reporter gene
drived by PAcP promoters in the presence of different concentrations of NaB. Cells were
harvested and the CAT activity was determined. The values represent the means ± SD of
three independent experiments (n=3×3). *p < 0.05; **p < 0.01; ***p < 0.001.
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Fig.2.
Dosage and kinetic effects of HDAC inhibitors on cPAcP protein expression in LNCaP C-81
cells. LNCaP C-81 cells that were seeded at a density of 5×105 cells/T25 for 2 days in
regular medium were treated with different concentrations of (A) NaB or (B) VPA for 48 hr,
or treated with (C) 1 mM NaB or (D) 1 mM VPA for different time periods. The total
protein was harvested and subjected to western blot analyses of cPAcP protein expression.
(D) The acetylation and the methylation levels of H3 and H4 proteins were also analyzed in
VPA-treated C-81 cells for different time periods. ?-Actin was analyzed and used as a
loading control in each experiment. Similar results were obtained from five sets of
independent experiments.
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Fig. 3.
Effect of cPAcP expression on VPA growth suppression and VPA effect on androgen
sensitivity of PCa cell lines. (A) LNCaP C-81 cells were plated at a density of 1×105 cells/
well in 6-well plates for 72 hr and then transfected with PAcP shRNA-126 plasmids. Control
cells were transfected with the vector containing the scramble DNA. Five hours after
transfection, the cells were fed with RPMI medium containing 10% FBS for 24 hr. The cells
were then treated with 1mM VPA for 48 hr. The cell numbers were counted. The ratio of
cell growth was calculated by normalizing the cell number to that of the control cells
transfected with the control vector and treated with the solvent alone. The result shown is
the average from two sets of independent experiments in triplicates (left panel, n= 3×2).
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Total cell lysate proteins from 3-day VPA treatments were analyzed for cPAcP protein
expression. ?-Actin was used as a loading control (right panel). (B) LNCaP C-81; (C) C4-2;
(D) MDA PCa2b-AI cells were plated at a density of 3×104, 3×104 and 1×105 cells/well,
respectively, in 6-well plates for 72 hr and then treated with 1 mM VPA. Control cells were
treated with solvent alone. After 48 hr VPA treatment, cells were maintained in a steroid-
reduced medium in the absence or presence of 10 nM DHT for 48 hr. The cell numbers were
counted. The ratio of cell growth was calculated by normalizing the cell number to that of
the control cells without any treatment (column #1). The result shown is the average from
three sets of independent experiments in triplicates (n= 3×3). Total cell lysate proteins from
3-day DHT treatment were analyzed for cPAcP, PSA, AR protein expression. The AR
protein in Fig. 3B was obtained after 3-hr hybridization with anti-AR Ab followed by an
exposure time period of less than 1 min; while the AR proteins in Fig. 3C & 3D were
obtained after overnight hybridization with anti-AR Ab and with an exposure time period of
1 hr. ?-Actin was used as a loading control and it was obtained with the same reaction time
periods.
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Fig. 4.
Effects of VPA on cPAcP protein expression and ErbB-2 tyrosyl phosphorylation. LNCaP
C-81 cells were plated in three cell dinsities (0.3, 0.5 and 1×106 cells/T25) in regular
medium for 2 days and then treated with 1 mM VPA for 48 hr. The cells were harvested and
the total protein was subjected to western blot analyses of functional proteins expression.
VPA effects on cPAcP protein expression, ErbB-2 phosphorylation at Tyr1221/2 and Tyr1248,
histone H3 and H4 acetylation and methylation, JNK and p38 phosphorylation, Bcl-2 and
Bax protein levels. ?-Actin was detected as a loading control. The data shown is a
representative from three sets of independent experiments.
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Fig. 5.
Effects of HDAC inhibitors on cell cycle distribution, apoptosis and cell cycle protein
expression in LNCaP C-81 cells. LNCaP C-81 cells were plated in regular medium for 48 hr
and treated with 1 mM NaB, 1 mM VPA or 300 nM TSA for 48 hr. All cells were harvested
and subjected to cell cycle analyses using flow cytometry and western blot analyses of
indicated proteins. (A) Cell cycle analyses. The data shown is the mean of three sets of
independent experiments. (B) Western blot analyses. The total cellular lysate proteins were
analyzed for cPAcP protein, ErbB-2 phosphorylation, histone H3/H4 acetylation and
methylation, AR, cPSA, cyclin B1 and D1, PCNA and p21 protein levels. ?-Actin was
analyzed as a loading control in each experiment. The data shown is a representative of three
sets of independent experiments.
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